Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity

Fuad S Shihab1, William M Bennett, Jorge Isaac

  • 1Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA. Fuad.Shihab@hsc.utah.edu

Kidney International
|March 13, 2003
PubMed
Abstract

Insights

Nitric oxide blockade increases vascular endothelial growth factor (VEGF) in cyclosporine (CsA) nephrotoxicity, while enhancement decreases it. VEGF likely acts via the KDR/Flk-1 receptor in CsA-induced fibrosis.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Vascular Endothelial Growth Factor (VEGF) mediates angiogenesis, wound healing, and inflammation via tyrosine kinase receptors Flt-1 and KDR/Flk-1.
  • Previous studies indicated VEGF upregulation in chronic cyclosporine (CsA) nephrotoxicity, with l-arginine (l-Arg) improving and N-nitro-l-arginine-methyl ester (L-NAME) worsening fibrosis.

Purpose of the Study:

  • To investigate the role of nitric oxide (NO) modulation on VEGF expression in a rat model of chronic CsA nephrotoxicity.

Main Methods:

  • Rats received CsA with or without L-NAME or l-Arg.
  • Physiological, histological, and molecular analyses (Northern blot, Western blot, immunohistochemistry) were performed.
  • Evaluated mRNA and protein expression of VEGF, Flt-1, and KDR/Flk-1.

Main Results:

  • L-NAME exacerbated renal dysfunction and histology, while l-Arg showed beneficial effects in CsA-treated rats.
  • CsA increased VEGF mRNA and protein; L-NAME further elevated it, whereas l-Arg significantly reduced it.
  • KDR/Flk-1 mRNA expression paralleled VEGF modulation, while Flt-1 expression remained unchanged. NO modulation did not affect vehicle-treated rats.

Conclusions:

  • VEGF expression in CsA nephrotoxicity is modulated by nitric oxide: increased by blockade and decreased by enhancement.
  • VEGF likely exerts its effects through the KDR/Flk-1 receptor.
  • VEGF may play a role in CsA-induced fibrosis, potentially independently or via nitric oxide pathways.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...